Cannabidiol is a Schedule 1 equivalent narcotic across the GCC, so clearing the SFDA Controlled Drug Board matters more than efficacy.

Cannabidiol (Epidiolex) is classified as a Schedule 1 equivalent narcotic under GCC/SFDA drug scheduling and is not available through any legal channel in Saudi Arabia, UAE, Qatar, or Kuwait. Stiripentol plus valproate and clobazam is the de-facto GCC standard of care as a result, meaning roughly 60% of the US Dravet pharmacological armamentarium is legally unavailable in the region. Fenfluramine (Fintepla)'s GCC controlled-substance status is unresolved and pending SFDA board review, adding further uncertainty to any competitor entering the region.

This creates a distinctive clinical argument: GCC Dravet patients on the stiripentol-only backbone experience 10-15 seizures a month, versus a US optimal of 3-5 a month on cannabidiol plus fenfluramine, a gap driven by the access barrier rather than treatment response. SUDEP risk tracks with seizure frequency, so GCC's suboptimal control implies a higher SUDEP risk band, 2-5% a year, than the US at 1-3%. GCC Dravet prevalence is estimated at 200-400 patients, with fewer than 100 optimally treated and 200-300 underserved on stiripentol alone. SCN1A genetic testing, the diagnostic gold standard, is ordered in only 30-40% of clinically suspected cases outside KFSH&RC.

Classification is existential here; efficacy data alone will not clear this gate.

Five questions this report answers:

Q1 - What must a new Dravet agent prove to clear the SFDA Controlled Drug Board?

Q2 - How large is the GCC Dravet population given the SCN1A testing gap?

Q3 - What NPHC and paediatric-neurology groundwork needs to start before SFDA approval?

Q4 - What determines whether a pre-launch Dravet syndrome agent succeeds commercially in the GCC?

Q5 - What deliverables and sourcing standard back every AXLRx GCC Dravet assessment?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #GCC #SFDA #Epilepsy #RareDisease #LaunchReadiness

Live report page:  https://axlrx.ai/dravet-syndrome/gcc/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/